HISTORY: 54 y.o. male 54 p/w one week of feeling off balance which is causing him to fall. PMH of L temporoparietal glioblastoma multiforme s/p craniotomy and debulking and XRT in 2008, temozolomide and several rounds of bevacizumab.   MEDICATIONS: Current Facility-Administered Medications: PHENobarbital (LUMINAL) injection 130 mg cyanocobalamin tablet 1,000 mcg dexamethasone (DECADRON) injection 4 mg dextrose 50% injection 25 mL dextrose 50% injection 50 mL glucagon (human recombinant) (GLUCAGEN) injection 1 mg insulin lispro (HumaLOG) injection 1-5 Units docusate sodium (COLACE) capsule 100 mg carBAMazepine (TEGRETOL) tablet 400 mg carBAMazepine (TEGRETOL) tablet 600 mg pantoprazole (PROTONIX) EC tablet 40 mg sodium chloride 0.9 % injection (flush) 10 mL sodium chloride 0.9 % injection (flush) 10 mL enoxaparin (LOVENOX) injection 40 mg LORazepam (ATIVAN) injection 2 mg acetaminophen (TYLENOL) tablet 500 mg aclidinium (TUDORZA PRESSAIR) inhalation 400 mcg gabapentin (NEURONTIN) tablet 600 mg metoprolol tartrate (LOPRESSOR) tablet 25 mg oxyCODONE-acetaminophen (PERCOCET) 5-325 mg per tablet 1 tablet senna (SENOKOT) tablet 2 tablet clonazePAM (KLONOPIN) tablet 0.5 mg   SEDATION: None  TECHNIQUE: A 21 channel electroencephalogram (EEG) was recorded using the International 10-20 system with T1/T2 electrodes and utilized a NicOne system. This was a technically satisfactory record and included a single channel of EKG.   DAY 1 (09/29/16, 14:14 - 9/30/2016, 08:00)  BACKGROUND: No posterior dominant rhythm was present. Background activity was characterized by diffuse delta and theta activity with absence of the expected anterior to posterior gradient of frequencies.  Sleep was not captured but state changes noted.  PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM):  None  EPILEPTIFORM ACTIVITY:  Multiple and frequent (~15 per hour) electrographic seizures arising from the left posterior quadrant P3/T5 and at time T3 that can last ~3 min. They slow down in frequency at 10PM and by 1AM they are occuring ~ 5 per hour.   EVENTS: no clinical correlate to the seizures   EKG: A single lead captured 90 bpm  DAY 1 IMPRESSION & CLINICAL CORRELATION: This is an abnormal long-term video EEG due to electrographic status epilepticus arising from the left posterior quadrant and mid-temporal region. In addition, there is diffuse background slowing and absent alpha rhythm.  These findings are etiologically nonspecific indicators of moderate diffuse cerebral dysfunction.  ----------------------------------------------------------------- DAY 2 (09/30/16, 8:00 - 10/01/2016, 08:00)  BACKGROUND: No posterior dominant rhythm was present. Background activity was characterized by diffuse delta and theta activity with absence of the expected anterior to posterior gradient of frequencies.  Sleep was not captured but state changes noted.  PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM):  None  EPILEPTIFORM ACTIVITY:  Multiple and frequent (~15 per hour) electrographic seizures arising from the left posterior quadrant P3/T5 and at time T3 that can last ~3 min.   EVENTS: no clinical correlate to the seizures   EKG: A single lead captured 90 bpm  DAY 2 IMPRESSION & CLINICAL CORRELATION: This is an abnormal long term video EEG due to electrographic status epilepticus arising from the left posterior quadrant and mid-temporal region. In addition, there is diffuse background slowing and absent alpha rhythm.  These findings are etiologically nonspecific indicators of moderate diffuse cerebral dysfunction.  ----------------------------------------------------------------- DAY 3 (10/01/16, 8:00 - 10/02/2016, 08:00)  BACKGROUND: No posterior dominant rhythm was present. Background activity was characterized by diffuse delta and theta activity with absence of the expected anterior to posterior gradient of frequencies.  Sleep was not captured but state changes noted.  PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM):  None  EPILEPTIFORM ACTIVITY:  Multiple and frequent (~10 per hour) electrographic seizures arising from the left posterior quadrant P3/T5 and at time T3 that can last ~3 min.   EVENTS: no clinical correlate to the seizures   EKG: A single lead captured 90 bpm  DAY 3 IMPRESSION & CLINICAL CORRELATION: This is an abnormal long term video EEG due to electrographic status epilepticus arising from the left posterior quadrant and mid-temporal region. In addition, there is diffuse background slowing and absent alpha rhythm.  These findings are etiologically nonspecific indicators of moderate diffuse cerebral dysfunction.   -----------------------------------------------------------------   DAY 4 (10/02/2016, 10:00 - 10/3/2016, 10:00) Current Facility-Administered Medications: LORazepam (ATIVAN) 50 mg in sodium chloride 0.9 % 50 mL infusion carBAMazepine (TEGRETOL) tablet 400 mg cyanocobalamin tablet 1,000 mcgdexamethasone (DECADRON) injection 4 mg LORazepam (ATIVAN) injection 2 mg gabapentin (NEURONTIN) tablet 600 mgoxyCODONE-acetaminophen (PERCOCET) 5-325 mg per tablet 1 tablet clonazePAM (KLONOPIN) tablet 0.5 mg An ativan drip was started on the evening of 10/02/2016 and 100 mg pyridoxine was given.   BP 101/84  Pulse (!) 107  Temp 98.7 °F (37.1 °C)  Resp 12  Ht 1.803 m (5' 10.98")  Wt 73.9 kg (162 lb 14.7 oz)  SpO2 100%  BMI 22.72 kg/m2 Lab Results      Component                Value               Date                                     PHENOBARB                70.0 (HH)           10/02/2016            BACKGROUND: No improvement, at times attenuates diffusely. At times more of a diffuse delta pattern  GENERALIZED SLOWING: more attenuated at times  FOCAL SLOWING: No change  PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM): no change.  Prominent beta, breach  Burst suppression pattern noted, increasing by the afternoon with alpha frequency bursts and then attenuation.  SPORADIC EPILEPTIFORM ACTIVITY: infrequent, aside from seizures  Seizures: Sporadic seizures, Variable patterns  1. particularly P3/T5, often brief, particularly at 2 and 6 PM 2. C3 paroxysmal seizures, often with fast activity, of approximately 30- 90 seconds duration.  EKG: A single EKG lead captured HR 107 BPM   DAY 4 IMPRESSION & CLINICAL CORRELATION  Ongoing seizures, with variable ictal patterns, now some originate at C3.  More suppressed background may be result of medication use or progression of CNS disease.     -----------------------------------------------------------------  DAY 5 (October 3, 2016 - 10/4/2016, 10:00) Current Facility-Administered Medications: LORazepam (ATIVAN) 50 mg in sodium chloride 0.9 % 50 mL infusion pyridoxine (vitamin B6) (B-6) injection 100 mg gabapentin (NEURONTIN) tablet 800 mg carBAMazepine (TEGRETOL) tablet 400 mg cyanocobalamin tablet 1,000 mcg dexamethasone (DECADRON) injection 4 mg glucagon (human recombinant) (GLUCAGEN) injection 1 mg insulin lispro (HumaLOG) injection 1-5 Units docusate sodium (COLACE) capsule 100 mg pantoprazole (PROTONIX) EC tablet 40 mg LORazepam (ATIVAN) injection 2 mg Ativan Drip acetaminophen (TYLENOL) tablet 500 mg aclidinium (TUDORZA PRESSAIR) inhalation 400 mcg oxyCODONE-acetaminophen (PERCOCET) 5-325 mg per tablet 1 tablet senna (SENOKOT) tablet 2 tablet clonazePAM (KLONOPIN) tablet 0.5 mg BP 97/75  Pulse (!) 105  Temp 99.4 °F (37.4 °C) (Axillary)  Resp 12  Ht 5' 10.98" (1.803 m)  Wt 162 lb 14.7 oz (73.9 kg)  SpO2 99%  BMI 22.72 kg/m2 Lab Results      Component                Value               Date                            PHENOBARB                70.0 (HH)           10/02/2016                CBMZ                     5.3                 06/22/2015            BACKGROUND: increasingly slow GENERALIZED SLOWING: by the afternoon of the 3rd, intermittent B-S pattern FOCAL SLOWING: No change PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM): None SPORADIC EPILEPTIFORM ACTIVITY: Rare (<1hour)   EVENTS: ongoing electrographic seizures from T5, P3 or C3 of 30-90 seconds duration which abate at 1:40 PM   EKG: A single EKG lead captured  HR 106  DAY 5 IMPRESSION & CLINICAL CORRELATION: Status epilepticus, resolving at least in the short term with lorazepam drip.    -----------------------------------------------------------------  DAY6 (10/4/2016, 10:00 - 10/5/2016, 10:00) has a current medication list which includes the following prescription(s): oxycodone-acetaminophen (PERCOCET) - Take 1 tablet by mouth every 4 hours as needed for Pain. Indications: last dose 3 months, acetaminophen (TYLENOL EXTRA STRENGTH) - Take 1 tablet by mouth every 6 hours as needed for Pain, oxycodone (ROXICODONE) - Take 1 tablet by mouth every 6 hours as needed for Pain for up to 30 days, senna-docusate (SENNOSIDES-DOCUSATE SODIUM) - Take 2 tablets by mouth daily as needed for Constipation, metoprolol tartrate (LOPRESSOR) - Take 1 tablet by mouth 2 times daily, aclidinium (TUDORZA PRESSAIR) - Inhale 1 each into the lungs every 12 hours, carbamazepine (TEGRETOL XR) - One tablet po bid for seizure prevention, senna (SENNA LAXATIVE) - Take 2 tablets by mouth at bedtime, gabapentin (NEURONTIN) - Take 2 tablets by mouth 3 times daily, umeclidinium (INCRUSE ELLIPTA) - Inhale 1 puff into the lungs daily, and promethazine-codeine (PHENERGAN WITH CODEINE) - Take 5 mLs by mouth 4 times daily as needed for Cough, and the following Facility-Administered Medications: phenobarbital (LUMINAL), phenobarbital (LUMINAL), lorazepam in 0.9% sod chloride (ATIVAN), pyridoxine (vitamin b6) (B-6), gabapentin (NEURONTIN), carbamazepine (TEGRETOL), cyanocobalamin, dexamethasone (DECADRON), dextrose 50%, dextrose 50%, glucagon (human recombinant) , lorazepam (ATIVAN), and acetaminophen (TYLENOL EXTRA STRENGTH)aclidinium (TUDORZA PRESSAIR)oxycodone-acetaminophen (PERCOCET)senna (SENNA LAXATIVE)clonazepam (KLONOPIN).  BP 100/79  Pulse 92  Temp 98.7 °F (37.1 °C)  Resp 12  Ht 1.803 m (5' 10.98")  Wt 78.7 kg (173 lb 8 oz)  SpO2 100%  BMI 24.21 kg/m2 BACKGROUND: intermittently increasingly slow  GENERALIZED SLOWING: No improvement. Despite reduction in Lorazepam, intermittent bursts slow delta;  intermittently attenuates  FOCAL SLOWING: No change  PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM): intermittent paroxsymal bursts of alpha/beta of 20-30 sec duration followed by suppressoin  SPORADIC EPILEPTIFORM ACTIVITY: Rare (<1hour) C3 sharps  EVENTS: None  EKG: A single EKG lead captured  R 90 BPM  DAY 6 IMPRESSION & CLINICAL CORRELATION Ativan was discontinued by the AM of 10-5-2016. No seizures were noted, but the background remains markedly slow.  The EEG findings and MRI report were reviewed in team conference on October 4, 2016. There is no option for epilepsy surgery at this time.   -----------------------------------------------------------------  DAY 7 (10/5/2016, 06:00 - 10/6/2016, 06:00) BP 109/82  Pulse 98  Temp 98.4 °F (36.9 °C) (Tympanic)  Resp 12  Ht 1.803 m (5' 10.98")  Wt 72.3 kg (159 lb 6.3 oz)  SpO2 100%  BMI 22.24 kg/m2 has a current medication list which includes the following prescription(s): oxycodone-acetaminophen (PERCOCET) - Take 1 tablet by mouth every 4 hours as needed for Pain. Indications: last dose 3 months, , oxycodone (ROXICODONE) - Take 1 tablet by mouth every 6 hours as needed for Pain for up to 30 days, senna-docusate (SENNOSIDES-DOCUSATE SODIUM) - Take 2 tablets by mouth daily as needed for Constipation, metoprolol tartrate (LOPRESSOR) - Take 1 tablet by mouth 2 times daily, aclidinium (TUDORZA PRESSAIR) - Inhale 1 each into the lungs every 12 hours, carbamazepine (TEGRETOL XR) - One tablet po bid for seizure prevention, senna (SENNA LAXATIVE) - Take 2 tablets by mouth at bedtime, gabapentin (NEURONTIN) - Take 2 tablets by mouth 3 times daily, umeclidinium (INCRUSE ELLIPTA) - Inhale 1 puff into the lungs daily, and promethazine-codeine (PHENERGAN WITH CODEINE) - Take 5 mLs by mouth 4 times daily as needed for Cough, and the following Facility-Administered Medications: pantoprazole (PROTONIX), phenobarbital (LUMINAL), gabapentin (NEURONTIN), dexamethasone (DECADRON), pyridoxine (vitamin b6) (B-6), carbamazepine (TEGRETOL), cyanocobalamin, dextrose 50%, dextrose 50%, glucagon (human recombinant) (SENNA LAXATIVE)clonazepam (KLONOPIN). Lab Results      Component                Value               Date                        PHENOBARB                51.5 (H)            10/04/2016                VALPROATE                54                  11/24/2014                CBMZ                     5.3                 06/22/2015            BACKGROUND: No change, remains asymmetric Intermittent bursts alpha/beta activity.   GENERALIZED SLOWING: No change- at times marked paroxysmal delta,    FOCAL SLOWING: No significant change, as EEG becomes more continuous, R side becomes continuous first.   PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM): None  SPORADIC EPILEPTIFORM ACTIVITY: Rare (<1hour) Sharply contoured slowing at T1 or small C3 sharps, fewer than previous days  EVENTS: None  EKG: A single EKG lead captured HR 90 BPM   DAY 7 IMPRESSION & CLINICAL CORRELATION No seizures. EEG is continuous, now sometimes reactive, + variable. There are focal features from each hemisphere.  R sharply contoured slowing is emerging in the later days of recording.   -----------------------------------------------------------------  DAY 8 (10/6/2016, 06:00 - 10/72016, 9:00) BP (!) 123/92 (BP Location: Right arm, Patient Position: Lying)  Pulse (!) 105  Temp 99.1 °F (37.3 °C) (Tympanic)  Resp (!) 22  Ht 5' 10.98" (1.803 m)  Wt 159 lb 6.3 oz (72.3 kg)  SpO2 100%  BMI 22.24 kg/m2  Current Facility-Administered Medications:  •  dexamethasone (DECADRON) injection 1 mg, 1 mg, IV Push, Q12H SCH, MBBS  •  gabapentin (NEURONTIN) capsule 800 mg, 800 mg, Oral, BID, 800 mg at 10/07/16 0924 •  PHENobarbital (LUMINAL) injection 90 mg, 90 mg, Intravenous, QHS, MBBS, 90 mg at 10/06/16 2134 •  pyridoxine (vitamin B6) (B-6) injection 100 mg, 100 mg, Intravenous, Daily, 100 mg at 10/07/16 0925 •  carBAMazepine (TEGRETOL) tablet 400 mg, 400 mg, Oral, Q12H, MBBS, 400 mg at 10/07/16 0830 •  cyanocobalamin tablet 1,000 mcg, 1,000 mcg, Oral, Daily, 1,000 mcg at 10/07/16 1313 •  clonazePAM (KLONOPIN) tablet 0.5 mg, 0.5 mg, Oral, BID PRN, 0.5 mg at 09/29/16 2355 Lab Results      Component                Value               Date                          PHENOBARB                51.5 (H)            10/04/2016                    BACKGROUND: Less asymmetric, transitions to more of a pattern of slow delta. Intermittent bursts alpha/beta activity. Spontaneous EOMS are seen,  GENERALIZED SLOWING: No change- at times marked paroxysmal delta, less notable on Oct 7.   FOCAL SLOWING: No significant change, as EEG becomes more continuous, R side becomes continuous first.  PAROXSYMAL ACTIVITY (NON-EPILEPTIFORM): None SPORADIC EPILEPTIFORM ACTIVITY: Rare (<1hour) Sharply contoured slowing at T1 or small C3 sharps, fewer than previous days  EVENTS: None  EKG: A single EKG lead captured HR 98 BPM   DAY 8 IMPRESSION & CLINICAL CORRELATION No seizures. EEG is continuous, now sometimes reactive, + variable. There are focal features from each hemisphere.  R sharply contoured slowing is emerging in the later days of recording.   FINAL IMPRESSION & CLINICAL CORRELATION This study shows resolution of status epilepticus.  However, this remains a very ill individual.  The EEG is now continuous but, the pattern remains markedly abnormal, many days after the Ativan has been discontinued.  These findings may be correlated with clinical imaging and overall picture
